NCT05885009 Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)
| NCT ID | NCT05885009 |
| Status | Recruiting |
| Phase | — |
| Sponsor | SOLTI Breast Cancer Research Group |
| Condition | Metastatic Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 240 participants |
| Start Date | 2023-03-28 |
| Primary Completion | 2026-03-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 240 participants in total. It began in 2023-03-28 with a primary completion date of 2026-03-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
HOPE Prostate is an observational study that aims at promoting research against metastatic prostate cancer by means of collective research led by patients (patient-centric trial). Patients with metastatic prostate cancer living in Spain will voluntarily register and fulfil their journey in the study through the study's digital tool. Mainly they are prompted to answer questionnaires about their disease, and to provide a blood sample and an archival tumor biopsy. In HOPE Prostate these samples will be genomically analyzed and every patient case will be presented in a multidisciplinary molecular advisory board (MAB). The MAB will issue a plain report explaining the significance of the results and will try to enumerate future therapeutic options that match patient history and his genomic profile. Finally, patients will have to answer short follow-up questionnaires twice a year for 3 years. The study data will allow us to advance implementing precision medicine to improve the management of current and specially future metastatic prostate cancer patients.
Eligibility Criteria
Inclusion Criteria: 1. Male patients living in Spain. 2. Age ≥18 years. 3. Signed informed consent before any screening procedure. 4. Metastatic PC of any subtype confirmed both pathologically and radiologically (stage IV disease). 5. The subjects must be about to receive, or receiving, or will have completed treatment for their metastatic disease with any line of treatment in either a clinical trial or the standard of care healthcare setting. 6. Eastern Cooperative Oncology Group (ECOG) 0-1. Exclusion Criteria: 1. Inability to consent or conform to the processes involved in a clinical study. 2. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Frequently Asked Questions
Who can join the NCT05885009 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Metastatic Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05885009 currently recruiting?
Yes, NCT05885009 is actively recruiting participants. Visit ClinicalTrials.gov or contact SOLTI Breast Cancer Research Group to inquire about joining.
Where is the NCT05885009 trial being conducted?
This trial is being conducted at Barcelona, Spain.
Who is sponsoring the NCT05885009 clinical trial?
NCT05885009 is sponsored by SOLTI Breast Cancer Research Group. The trial plans to enroll 240 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.